Internal Bra Mesh Lawsuit

Breast mesh lawsuits allege that some manufacturers promoted or allowed their mesh products to become widely used in breast reconstruction, augmentation, and revision procedures despite the fact that FDA has not cleared or approved any surgical mesh product for use in breast surgery. The FDA has specifically stated that the safety and effectiveness of surgical mesh in breast surgery, including augmentation and reconstruction, has not been determined.

These internal bra lawsuits allege that manufacturers of products such as AlloDerm, GalaFLEX, Phasix, AlloMax, FlexHD, Strattice, and DuroSorb marketed their devices for breast reconstruction, augmentation, and revision surgeries even though those breast-specific applications had not been adequately studied or cleared by the FDA. Patients were not warned. Surgeons were not given enough information. So when complications developed, including infection, mesh failure, chronic pain, implant loss, breast deformity, and the need for additional surgery, many women had no reason to connect their injuries to the mesh product placed inside them.

This page explains the internal bra mesh lawsuit. Our lawyers talk about what the legal claims are, who may be eligible, what complications may qualify, how to identify your mesh product, what evidence matters, and what these cases may be worth.

What Is Breast Mesh and How Is It Used in the Internal Bra Technique?

The surgical mesh used in breast surgery is a material implanted inside the breast to provide structural support for tissue and implants. The surgical technique that uses it is commonly called the internal bra, a self-explanatory term that describes how the mesh functions. Positioned beneath or over breast tissue, the mesh is intended to support the breast from within, in the same way a physical bra supports it from the outside.

Women generally undergo an internal bra procedure for three reasons. First, breast reconstruction surgery following a mastectomy, most often after a cancer diagnosis. Second, breast augmentation, where mesh is used to support implants and maintain shape over time. Third, revision or breast lift surgery, where mesh is used to correct or improve prior procedures.

There are two broad categories of breast mesh:

• Biologic mesh, or ADM: Derived from processed human or animal tissue, acellular dermal matrix acts as a biological scaffold that the patient’s own tissue gradually incorporates. Common brands include AlloDerm, FlexHD, AlloMax, and Strattice.
• Synthetic mesh: Made from man-made polymers, synthetic mesh may be resorbable, meaning it dissolves over time, or permanent, meaning it stays in the body indefinitely. Products that appear in this litigation include GalaFLEX, Phasix, and DuroSorb.

Women like the idea of mesh in breast surgery because the internal bra technique is supposed to reduce mechanical stress on surrounding tissue, support implants, and potentially extend the longevity of surgical results. The problem is that no surgical mesh product has been cleared or approved by the FDA specifically for use in breast surgery. That distinction may sound technical, but it matters. Patients and surgeons reasonably assume that a product promoted for breast reconstruction, augmentation, or revision surgery has been studied for that use. Plaintiffs allege that assumption was wrong.

If the mesh works without complications, many women never question it. But when serious complications occur, the lack of breast-specific FDA review, breast-specific studies, and breast-specific warnings becomes central to the lawsuit.

The Internal Bra Lawsuit: What the Legal Claim Actually Says

Breast mesh lawsuits rest on a straightforward legal theory. Manufacturers sold products for breast procedures that were generally cleared for soft tissue reinforcement, promoted those products for breast-specific uses, and failed to adequately warn patients or physicians about the risks of using mesh in the breast.

Understanding how mesh reached breast surgery starts with the FDA’s 510(k) clearance pathway. Under that process, a device can be cleared for market if FDA finds it substantially equivalent to a predicate device. That is not the same thing as FDA approval of the device for every later clinical use.

The mesh products at issue were cleared for repair and reinforcement of soft tissue where weakness exists. FDA has made clear that surgical mesh has not been cleared or approved for breast surgery, including augmentation or reconstruction, and that FDA has not determined the safety and effectiveness of surgical mesh for those breast surgery uses.

Plaintiffs allege that these products nevertheless became widely used in internal breast procedures and that manufacturers failed to adequately warn patients and physicians about the limits of the FDA clearance and the risks of using mesh in breast tissue. The key issue is not whether doctors may use a device off-label. They can. The issue is whether manufacturers gave adequate warnings and whether patients were told that the mesh being implanted in their bodies was not FDA-cleared or approved for breast reconstruction, augmentation, or revision surgery.

Product liability law, specifically failure-to-warn and defective design claims, forms the backbone of most internal bra cases. Some cases may also assert negligence, negligent misrepresentation, fraud, breach of warranty, or consumer protection claims, depending on the circumstances of the patient’s surgery and injury.

Off-Label Use Versus Off-Label Promotion

This distinction is important. Doctors often have legal discretion to use a medical device off-label when they believe it is appropriate for a particular patient. That is not usually the heart of the lawsuit.

The stronger legal issue is off-label promotion. Plaintiffs allege that manufacturers did more than sell a device cleared for general soft tissue reinforcement. They allegedly encouraged breast surgeons to use these products in breast reconstruction, augmentation, revision, and lift procedures without adequate breast-specific testing, without FDA clearance or approval for that use, and without warnings that matched the actual risk profile.

That is why these cases are primarily directed at manufacturers, not treating physicians. Surgeons often relied on the information manufacturers gave them. If the promotional materials, sales communications, training programs, or warnings understated the risk, then the manufacturer may be responsible for injuries that followed.

FDA Warnings on Breast Mesh: A Timeline

No surgical mesh product has been cleared or approved by the FDA for use in breast surgery, including breast augmentation or reconstruction. The FDA has also stated that the safety and effectiveness of surgical mesh in breast surgery has not been determined. That distinction matters enormously, and it is one that manufacturers have not always made clear to surgeons or patients.

These products entered the market through the FDA’s 510(k) clearance pathway. Many were cleared for general soft tissue repair or reinforcement, a broad category the FDA has not formally extended to breast surgery. Yet for years, manufacturers sold these products into operating rooms for exactly that purpose.

What This Timeline Means for the Breast Mesh Litigation

The progression of FDA attention tells a story that plaintiffs’ attorneys have been building cases around for years. The FDA eventually raised concerns, and the label language changed. But the women who underwent surgery in 2018, 2019, 2020, or earlier often did so without clear information that the mesh was not cleared or approved for breast surgery.

The 2023 label updates are great for women moving forward. But they are of little comfort to women who already had surgery without the benefit of that information. The central questions in this litigation are what manufacturers knew, when they knew it, what they told surgeons, and why breast-specific warnings did not appear earlier.

Breast Mesh Brands Under Legal Investigation

The following surgical mesh and ADM products are under active legal scrutiny in connection with breast mesh injuries. Manufacturers, including Allergan/LifeCell, Becton Dickinson, C.R. Bard, Integra LifeSciences, and MTF Biologics, are named in investigations. If your surgery involved any of these products, you should talk to a lawyer about your claim.

These are just the brands our lawyers are tracking now. If your mesh brand does not appear on this list, you may still have a viable internal bra lawsuit. An attorney can review your records and advise you on whether your specific product and injuries qualify.

Who May Qualify to File an Internal Bra Mesh Lawsuit

Women who had surgical mesh placed during breast surgery and later suffered complications may qualify to file a breast mesh lawsuit. You do not need to have every detail before speaking with a lawyer. A case review can help determine whether you may have a claim.

Do you need to have the mesh removed to bring a claim? No. Mesh removal is not a universal requirement. But the strongest cases usually involve revision surgery, implant loss, removal, significant infection, persistent pain, or compelling medical documentation connecting the complication to the mesh.

Our law firm is generally focused on cases involving a revision procedure or another serious complication. But do not screen yourself out too quickly. If you do not know what product was used, your surgical records should identify it, and an attorney can help obtain those records.

Internal Bra Complications: What Can Go Wrong

Breast surgery involving mesh can lead to serious complications, although many of these problems can also occur in breast implant surgery without mesh. The key issue in a mesh injury case is whether the mesh contributed to the complication, made it worse, required removal, or created risks that were not adequately disclosed before surgery.

The human body does not always tolerate foreign material. Whether the mesh is biologic or synthetic, the immune system can react in the weeks immediately following surgery or months or years later. Reported complications in breast mesh cases include infection, seroma, capsular contracture, mesh migration or failure, skin erosion, tissue necrosis, chronic pain, nerve symptoms, and implant loss.

A 2024 study published in Aesthetic Surgery Journal Open Forum reviewed synthetic mesh outcomes in alloplastic breast reconstruction and reported short-term complication data, including reoperation and implant loss outcomes. This type of literature matters because it helps compare the complication risks reported in medical studies with the warnings patients received before surgery.

How to Find Out If Mesh Was Used in Your Surgery

Many patients are never explicitly told that mesh was part of their procedure. Surgeons often describe the internal bra technique in general terms without naming specific products, and the details are buried in surgical records that patients rarely think to request.

You can do this yourself or, more likely, your attorney will do it for you. To identify whether mesh was used and which brand you received:

• Request your complete operative report from the hospital or surgical center. This document describes exactly what was done during your procedure, including any materials implanted.
• Look for device implant stickers. Hospitals often attach product stickers from implanted devices to the surgical record. These may contain the brand name, product code, lot number, and Unique Device Identifier.
• Review discharge paperwork and implant documentation cards given to you at the time of surgery. This can be a shortcut to finding the brand, but it is not necessary if you no longer have the paperwork.
• Call your surgeon’s office and ask directly whether mesh or acellular dermal matrix was used and, if so, the specific brand and product name.

Your medical records belong to you by law. We rarely have trouble obtaining them. If a provider creates obstacles to access, an attorney can issue a formal medical records request on your behalf. Identifying the specific product you received is one of the first steps our legal team will take when evaluating your claim.

Evidence That Strengthens a Breast Mesh Claim

Personal injury claims rest on documentation. You do not need everything assembled before speaking with an attorney, but gathering what you can now puts your case in a stronger position from the start.

Many women wait to seek legal advice because they are still in treatment or are not sure their situation rises to the level of a lawsuit. That hesitation is understandable, but it can cost you. Evidence disappears, statutes of limitations run, and the window to act can close without warning. You do not need a complete file before calling. We can listen to what happened, identify the records we need, and help determine whether the mesh may be connected to your injuries.

Breast Mesh Lawsuit Settlements and Potential Case Value

We are in the early innings of this litigation. As of 2026, there are no large-scale breast mesh settlements. Because the litigation is still developing, specific figures are difficult to provide. What is available is context from comparable mesh litigation.

In 2024, C.R. Bard reached a settlement estimated at more than $1 billion to resolve approximately 40,000 hernia mesh claims. The same manufacturer, Bard, now faces scrutiny over breast mesh products, including AlloMax and Phasix.

Hernia mesh and breast mesh cases involve different injuries, different medical uses, and different patient populations. But the hernia mesh litigation shows that mesh manufacturers can face major liability when plaintiffs prove that a product caused widespread harm and that warnings did not match what the company knew about risk.

These internal bra lawsuits may have significant settlement value, especially in cases involving revision surgery, implant loss, infection, permanent deformity, tissue damage, chronic pain, or evidence that the manufacturer promoted breast use despite knowing the product had not been adequately evaluated for that purpose.

The value of any individual breast mesh claim depends on several factors:

The internal documents will matter. Plaintiffs will want to know what manufacturers knew about breast-specific complication rates, when they knew it, how they described those risks internally, and whether the warnings given to surgeons matched the concerns reflected in company files.

From there, if defendants do not resolve the cases, bellwether trials may eventually help establish settlement ranges. These are early test cases that go to a jury verdict and give both sides a clearer picture of risk. The reality is that this process often takes time, especially once cases begin consolidating in federal or state court.

Frequently Asked Questions About Breast Mesh Lawsuits

Hiring an Internal Bra Mesh Lawyer

If you believe you have a claim in this litigation, our law firm wants to help you. These cases require product identification, medical record review, FDA and labeling analysis, statute of limitations review, and a close look at your complications and revision history.

Call 800-553-8082 or get a free, no-obligation consultation online. You do not need to know the brand of mesh before calling. If the facts suggest a viable claim, our lawyers can help identify the product and determine whether your injuries may fit the internal bra mesh litigation.